AML Blood Test – A new method for the early detection and prognosis of acute myeloid leukemia

Diagnosing acute myeloid leukemia (AML) is difficult due to the lack of specificity of symptoms. Thus, AML is often mistakenly diagnosed as an infection or a general fatigue.

Tragically, AML progresses extraordinarily fast. Thus, any delay in diagnosis/treatment results in a loss of precious time for life-saving chemotherapy. Scientists from the University of Bonn developed an innovative RNA-fingerprint-based test of peripheral blood samples. Data sets from more than 4.000 patients demonstrate a specificity of > 0,996 and a sensitivity of > 0,992. By using peripheral blood samples, the test is easily applicable. With the diagnosis also being fast and cost-efficient, the present invention is also applicable (as an exclusion diagnosis) by the general practitioner.

Weitere Informationen: PDF

PROvendis GmbH
Tel.: +49 (0)208/94105 10

Ansprechpartner
Dipl.-Ing. Alfred Schillert